^
Association details:
Evidence:
Evidence Level:
Resistant: B - Late Trials
New
Source:
Title:

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib

Excerpt:
PDGFRA mutations and KIT exon 11 insertion or duplication mutations were associated with favorable RFS, whereas KIT exon 9 mutations were associated with unfavorable outcome.
DOI:
10.1001/jamaoncol.2016.5751
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

Excerpt:
...- Gene mutation test report including c-kit exons 9,11,13 and 17 and platelet-derived growth factor receptor alpha (PDGFRA) exons 12 and 18...
Trial ID: